Skip to main content
TipRanks
Go Ultimate75% OFF

Pacific Biosciences (P09) Stock Price & Analysis

6 Followers

P09 Stock Chart & Stats

€1.65-€0.03(-1.73%)
At close: 5:30 PM GMT+1
€1€1.5€2€2.5Aug 24Sep 14Sep 22Oct 6Oct 15Nov 2Nov 16
Day’s Range
EUR 1.65 - EUR 1.74
52-Week Range
EUR 0.93 - EUR 2.97
Previous Close
EUR 1.68
Volume
N/A
Average Volume (3M)
1,690
Market Cap
EUR 518.01M
Enterprise Value
EUR 1.24B
Total Cash (Recent Filing)
EUR 199.42M
Total Debt (Recent Filing)
EUR 705.37M
Price to Earnings (P/E)
―
Beta
0.09
Next Earnings
Feb 18, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Clinical Growth

Clinical adoption is becoming a meaningful growth engine, with consumables revenue rising more than 20% year-over-year and testing moving toward commercialization. Greater clinical use can deepen recurring reagent demand, diversify customers beyond research markets, and support more durable platform utilization.

Installed-Base Expansion

Expansion of the Revio installed base strengthens PacBio’s razor-and-blades model because each placement can generate recurring consumables and service revenue. New customers, multi-instrument orders, and larger fleet deployments also increase utilization opportunities and reinforce workflow adoption.

Cost Reduction Roadmap

The planned reduction in compensation-related and development spending provides a defined path to lower operating expenses and reduced cash burn. If executed, these savings could extend financial runway, improve operating leverage, and move the company closer to sustainable cash generation.

Bears Say

Stressed Balance Sheet

Negative equity and substantial debt materially constrain financial flexibility while the company remains loss-making. This capital structure can limit investment choices, increase refinancing exposure, and make execution of product launches and commercial expansion more dependent on external financing.

Persistent Cash Burn

PacBio is still funding operations primarily through external capital rather than internally generated cash. Continued high cash burn reduces the resources available for research, commercialization, and debt management, while increasing the importance of achieving the company’s future cost and breakeven targets.

Margin Pressure

The decline in gross margin shows that product growth is not yet translating into stable economic performance. Higher component costs and transition expenses can compress contribution from instruments and consumables, making future profitability dependent on execution, scale benefits, and cost normalization.

Pacific Biosciences News

P09 FAQ

What was Pacific Biosciences’s price range in the past 12 months?
Pacific Biosciences lowest stock price was €0.93 and its highest was €2.97 in the past 12 months.
What is Pacific Biosciences’s market cap?
Pacific Biosciences’s market cap is €518.01M.
When is Pacific Biosciences’s upcoming earnings report date?
Pacific Biosciences’s next earnings report is estimated for Feb 18, 2027 (not yet confirmed), which is in 92 days.
How were Pacific Biosciences’s earnings last quarter?
Pacific Biosciences released its earnings results on Nov 04, 2026. The company reported -€0.107 earnings per share for the quarter, beating the consensus estimate of -€0.121 by €0.013.
Is Pacific Biosciences overvalued?
According to Wall Street analysts Pacific Biosciences’s price is currently Undervalued.
Does Pacific Biosciences pay dividends?
Pacific Biosciences does not currently pay dividends.
What is Pacific Biosciences’s EPS estimate?
Pacific Biosciences’s EPS estimate is -0.11.
How many shares outstanding does Pacific Biosciences have?
Pacific Biosciences has 312,926,730 shares outstanding.
What happened to Pacific Biosciences’s price movement after its last earnings report?
Pacific Biosciences reported an EPS of -€0.107 in its last earnings report, beating expectations of -€0.121. Following the earnings report the stock price went up 1.498%.
Which hedge fund is a major shareholder of Pacific Biosciences?
Hedge funds hold Pacific Biosciences shares: the largest hedge-fund position in Pacific Biosciences is 835,716,809 shares, and hedge funds decreased their holdings by 6.6M shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology